The clinicopathological significance of p53 and p21 expression in squamous cell carcinoma of hypopharyngeal cancer

Cancer Letters

Volumn 201, Issue 2, 2003, Pages 217-223

  Chien, Chih Yen ^a   Huang, Chao Cheng ^a   Cheng, Jiin Tsuey ^b   Chen, Ching Mei ^a   Hwang, Chung Feng ^a   Su, Chih Ying ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

Hypopharyngeal cancer; p21; p53

Indexed keywords

PROTEIN P21; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHARYNX CARCINOMA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGRESSION ANALYSIS; SQUAMOUS CELL CARCINOMA;

EID: 0242332765     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00484-1     Document Type: Article

References (37)

1. Pingree T.F., Davis R.K., Reichman O., Derrick L. Treatment of hypopharyngeal carcinoma: a 10-year review of 1362 cases. Laryngoscope. 97:1987;901-904.
2. Hoffman H.T., Karnell L.H., Shah J.P., Ariyan S., Brown G.S., Fee W.E., Glass A.G., Goepfert H., Ossoff R.H., Fremgen A.M. Hypopharyngeal cancer patient care evaluation. Laryngoscope. 107:1997;1005-1017.
3. WAF/CIP1 in squamous cell carcinoma of the pyriform sinus. Acta Otolaryngol. (Stockh). 118:1998;432-437.
4. Barzan L., Talamini R., Politi D., Minatel E., Gobitti C., Franchin G. Suamous cell carcinoma of the hypopharynx treated with surgery and radiation. J. Laryngol. Otol. 116:2002;24-28.
5. Tai S.K., Chang S.Y. Contralateral hemilaryngotracheal flap reconstruction of the hypopharynx in pyriform carcinoma resection. Laryngoscope. 109:1999;221-225.
6. Spector J.G., Sessions D.G., Emami B., Simpson J., Haughey B., Harvey J., Fredrickson J.M. Squamous cell carcinoma of the pyriform sinus: a nonrandomized comparison of the therapeutic modalities and long-term results. Laryngoscope. 105:1995;397-406.
7. Kraus D.H., Zelefsky M.J., Brock H.A., Huo J., Harrison L.B., Shah J.P. Combined surgery and radiation therapy for squamous cell carcinoma of the hypopharynx. Otolaryngol. Head Neck Surg. 116:1997;637-641.
8. Cox L.S., Lane D.P. Tumor suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. Bioessays. 17:1995;501-508.
9. Spruck C.H., Tsai Y.C., Huang D.P., Yang A.S., Rideout W.M., Gonzalez-Zulueta M., Choi P., Lo K.W., Yu M.C., Jones P.A. Absence of p53 gene mutations in primary nasopharyngeal carcinomas. Cancer Res. 52:1992;4787-4790.
10. Brennan J.A., Boyle J.O., Koch W.M., Goodman S.N., Hruban R.H., Eby Y.J., Couch M.J., Forastiere M., Sidransky D. Association between cigarette smoking and mutation of the p53 gene in squamous cell carcinoma of the head and neck. N. Eng. J. Med. 332:1993;712-717.
11. Boyle J.O., Hakim J., Koch W.M., van der Riet P., Hruban R.H., Roa R.A., Correo R., Eby Y.J., Ruppert J.M., Sidransky D. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res. 53:1993;4477-4480.
12. Nees M., Homann N., Discher H., Andl T., Enders C., Herold-Mende C., Schuhmann A., Bosch F.X. Expression of mutated p53 occurs in tumor-distant epithelia of head and neck cancer patients: A possible molecular basis for the development of multiple tumors. Cancer Res. 53:1993;4189-4196.
13. Nogueira C.P., Dolan R.W., Gooey J., Byahatti S., Vaughan C.W., Fuleihan N.S., Grillone G., Barker E., Domanowski G. Inactivation of p53 and amplification of cyclin D1 correlate with clinical outcome in head and neck cancer. Laryngoscope. 108:1998;345-350.
14. Starzynska T., Bromley M., Ghosh A., Stern P.L. Prognostic significance of p53 overexpression in gastric and colorectal carcinomas. Br. J. Cancer. 66:1992;558-562.
15. Isola J., Visakorpi T., Holli K., O P. Association of over expression of tumor suppressor p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J. Natl Cancer Inst. 84:1992;1109-1114.
16. Moch H., Sauter G., Gasser T.C., Buchholz N., Bubendorf L., Richter J., Jiang F., Dellas A., Mihatsch M.J. p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma. Urol. Res. 25:(suppl 1):1997;S25-S30.
17. O'Hanlon D.M., Kiely M., MacConmara M., Al-Azzawi R., Connolly Y., Jeffers M., Keane F.B. An immunohistochemical study of p21 and p53 expression in primary node-positive breast carcinoma. Eur. J. Surg. Oncol. 28:2002;103-107.
18. Vielba R., Bilbao J., Eng C., Ispizua A., Zabalza I., Alfaro J., Rezola R., Moreno E., Elorriaga J., Alonso I., Baroja A., de la Hoz C. p53 and cyclin D1 as prognostic factors in squamous cell carcinoma of larynx. Laryngoscope. 113:2003;167-172.
19. Cox L.S. Multiple pathways control cell growth and transformation: overlapping and independent activities of p53 and p21Cip1/WAF1/Sdi1. J. Pathol. 183:1997;134-140.
20. Dotto G.P. p21(WAF1/Cip1): more than a break to the cell cycle? Biochim. Biophys. Acta. 1471:2000;M43-M56.
21. Flores-Rozas H., Kelman Z., Dean F.B., Pan Z.Q., Harper J.W., Elledge S.J., O'Donnell M., Hurwitz J. Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme. Proc. Natl Acad. Sci. USA. 91:1994;8655-8659.
22. Li R., Waga S., Hannon G.J., Beach D., Stillman B. Differential effects by the p21 cdk inhibitor on PCNA-dependent DNA replication and repair. Nature. 371:1994;534-537.
23. Yuen P.W., Chow V., Choy J., Lam K.Y., Ho W.K., Wei W.I. The clinicopathologic significance of p53 and p21 expression in the surgical management of lingual squamous cell carcinoma. Am. J. Clin. Pathol. 116:2001;240-245.
24. Wakasugi E., Kobayashi T., Tamaki Y., Ito Y., Miyashiro I., Komoike Y., Takeda T., Shin E., Takatsuka Y., Kikkawa N., Monden T., Monden M. p21(Waf1/Cip1) and 53 protein expression in breast cancer. Am. J. Clin. Pathol. 107:1997;684-691.
25. WAF1. Cancer Res. 55:1995;4536-4539.
26. WAF1 is heterogenous and unrelated to proliferation index in human ovarian carcinoma. Int. J. Cancer. 63:1995;611-615.
27. Byrne R.L., Wilson Horne C.H., Robinson M.C., Autzen P., Apakama I., Bishop R.I., Neal D.E., Hamdy F.C. The expression of waf-1, p53, and bcl-2 in prostatic adenocarcinoma. Br. J. Urol. 79:1997;190-195.
28. Mineta H., Miura K., Suzuki I., Takebayashi S., Misawa K., Ueda Y., Ichimura K. p27 expression correlates with prognosis in patients with hypopharyngeal cancer. Anticancer Res. 19:1999;4407-4412.
29. Frank J.L., Bur M.E., Garb J.L. p53 tumor suppressor oncogene expression in squamous cell carcinoma of the hypopharynx. Cancer. 73:1994;181-186.
30. el-Deiry W.S., Harper J.W., O'Connor P.M., Velculescu V.E., Canman C.E., Jackman J., Pietenpol J.A., Burrell M., Hill D.E., Wang Y. WAF/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54:1994;1169-1174.
31. Datto M.B., Li Y., Panus J.F., Howe D.J., Xiong Y., Wang X.F. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc. Natl Acad. Sci. USA. 92:1995;5545-5549.
32. Michieli P., Chedid M., Lin D., Pierce J.H., Mercer W.E., Givol D. Induction of WAF1/CIP1 by a 53-independent pathway. Cancer Res. 54:1994;3391-3395.
33. Patel V., Lahusen T., Sy T., Sausville E.A., Gutkind J.S., Senderowicz A.M. Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest. Cancer Res. 62:2002;1401-1409.
34. Zhang W., Grasso L., McClain C.D., Gambel A.M., Cha Y., Travali S., Deisseroth A.B., Mercer W.E. p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/ macrophage differentiation. Cancer Res. 55:1995;668-674.
35. Jiang M., Shao Z.M., Wu J., Lu J.S., Yu L.M., Yuan J.D., Han Q.X., Shen Z.Z., Fontana J.A. p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis. Int. J. Cancer. 74:1997;529-534.
36. Osman I., Sherman E., Singh B., Venkatraman E., Zelefsky M., Bosl G., Scher H., Shah J., Shaha A., Kraus D., Cordon-Cardo C., Pfister D.G. Alteration of p53 pathway in squamous cell carcinoma of the head and neck: impact on the treatment outcome in patients treated with larynx preservation intent. J. Clin. Oncol. 20:2002;2980-2987.
37. Rowley H., Roland J., Helliwell T.R., Caslin A., Kinsella A.R., Jones A.S. p53 protein expression in tumours from head and neck subsites, larynx and hypopharynx, and differences in relationship to survival. Clin. Otolaryngol. 23:1998;57-62.